Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 7/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 8/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909593 | 1.00 | FASN (0.48) | FASNPFKFB3PIK3CDP2RX3BRD4 | |
| SCHEMBL11920986 | 0.89 | FASN (0.50) | FASNPFKFB3P2RX3BRD4 | |
| SCHEMBL10000 | 0.87 | BRD4 (0.53) | FASNPFKFB3BRD4 | |
| SCHEMBL22220896 | 0.87 | BRD4 (0.53) | FASNPFKFB3BRD4 | |
| SCHEMBL9999 | 0.87 | BRD4 (0.53) | FASNPFKFB3BRD4 | |
| SCHEMBL11011 | 0.86 | KDM4E (0.49) | FASNPIK3CDP2RX3BRD4 | |
| SCHEMBL22220882 | 0.86 | KDM4E (0.49) | FASNPIK3CDP2RX3BRD4 | |
| SCHEMBL22220920 | 0.86 | BRD4 (0.49) | FASNPIK3CDP2RX3BRD4 | |
| SCHEMBL10940 | 0.86 | BRD4 (0.49) | FASNPIK3CDP2RX3BRD4 | |
| SCHEMBL11010 | 0.86 | KDM4E (0.49) | FASNPIK3CDP2RX3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885PFKFB3 262/4885PIK3CD 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.